140 related articles for article (PubMed ID: 26548560)
1. PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway.
Zhang Z; Zhang G; Kong C; Gong D
Mol Med Rep; 2016 Jan; 13(1):333-8. PubMed ID: 26548560
[TBL] [Abstract][Full Text] [Related]
2. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
3. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
4. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
5. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
Xing X; Zhang L; Wen X; Wang X; Cheng X; Du H; Hu Y; Li L; Dong B; Li Z; Ji J
Anticancer Drugs; 2014 Nov; 25(10):1129-40. PubMed ID: 25035961
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
8. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
10. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
11. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.
Feng H; Yang Z; Bai X; Yang M; Fang Y; Zhang X; Guo Q; Ning H
Int J Mol Med; 2018 Apr; 41(4):2099-2107. PubMed ID: 29344639
[TBL] [Abstract][Full Text] [Related]
13. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
[TBL] [Abstract][Full Text] [Related]
14. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
[TBL] [Abstract][Full Text] [Related]
15. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
16. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
[TBL] [Abstract][Full Text] [Related]
17. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
18. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
19. Significance of filamin A in mTORC2 function in glioblastoma.
Chantaravisoot N; Wongkongkathep P; Loo JA; Mischel PS; Tamanoi F
Mol Cancer; 2015 Jul; 14():127. PubMed ID: 26134617
[TBL] [Abstract][Full Text] [Related]
20. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
Zhao L; Yue P; Khuri FR; Sun SY
Cancer Res; 2013 Mar; 73(6):1946-57. PubMed ID: 23319802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
